The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses.

Abstract

: Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV-related liver cirrhosis and hepatocellular carcinoma. The use of direct-acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5-8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV.

• Authors: Eui-Cheol Shin, Ji Won Han, Wonseok Kang, Takanobu Kato, Seong-Jun Kim, Jin Zhong, Seungtaek Kim, Su-Hyung Park, Pil Soo Sung, Koichi Watashi, Jun Yong Park, Marc P Windisch, Jong-Won Oh, Takaji Wakita, Kwang-Hyub Han, Sung Key Jang
• Journal: Viruses (Viruses) Vol. 12 Issue 3 (03 11 2020) ISSN: 1999-4915 [Electronic] Switzerland
• PMID: 32168867 (Publication Type: Congress, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Viral Vaccines

Topics

• Adaptive Immunity
• Antiviral Agents (pharmacology, therapeutic use)
• Disease Management
• Disease Susceptibility
• Hepacivirus (physiology)
• Hepatitis C (complications, drug therapy, prevention & control, virology)
• Host-Pathogen Interactions (immunology)
• Humans
• Immunity, Innate
• Liver Cirrhosis (etiology)
• Liver Neoplasms (etiology)
• Viral Vaccines (administration & dosage, immunology)
• Virus Assembly
• Virus Internalization
• Virus Replication